Mesoblast
Developing and commercialising allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases. Learn more
Launch date
Employees
Market cap
AUD1.1b
Enterprise valuation
AUD1.2b (Public information from Sep 2024)
Share price
AUD1.03 MSB.AX
Company register number 109431870
Melbourne Victoria (HQ)
Authorizing premium user...